|Trade names||Symkevi, Symdeko|
|Main uses||Cystic fibrosis|
|Side effects||Nausea, headache, diarrhea, dizziness|
Tezacaftor/ivacaftor, sold under the brand name Symdeko, is a combination medication of tezacaftor and ivacaftor used to treat cystic fibrosis. It is only used in people with specific mutations. It is taken by mouth.
Common side effects include nausea, headache, diarrhea, and dizziness. Other side effects may include liver problems and cataracts. In those with significant liver problems a lower dose may be required. Tezacaftor increases the number of CFTR while ivacaftor increases the ability of CFTR.
The combination was approved for medical use in the United States and Europe in 2018. In the United States it costs about 304,000 USD per year as of 2021. It became available in the United Kingdom in 2020 at a cost of about £82,000 per year.
It may be used in people over the age of 5.
A combination tablet of tezacaftor 100 mg with ivacaftor 150 mg is taken in the am while a ivacaftor 150 mg tablet is taken in the evening.
- "Tezacaftor and Ivacaftor Monograph for Professionals". Drugs.com. Archived from the original on 27 February 2021. Retrieved 8 October 2021.
- "Symkevi". Archived from the original on 8 January 2021. Retrieved 8 October 2021.
- "SYMDEKO™ (tezacaftor/ivacaftor) tablets; (ivacaftor) tablets, for oral use" (PDF). Archived (PDF) from the original on 9 June 2021. Retrieved 8 October 2021.
- "Symdeko Prices, Coupons & Patient Assistance Programs". Drugs.com. Archived from the original on 11 November 2020. Retrieved 8 October 2021.
- "Tezacaftor + ivacaftor". SPS - Specialist Pharmacy Service. 29 December 2015. Archived from the original on 26 February 2021. Retrieved 8 October 2021.